The University of Chicago Header Logo

Connection

Mark J. Ratain to Endpoint Determination

This is a "connection" page, showing publications Mark J. Ratain has written about Endpoint Determination.
Connection Strength

2.157
  1. Critical importance of correctly defining and reporting secondary endpoints when assessing the ethics of research biopsies. Clin Trials. 2024 Oct; 21(5):650-656.
    View in: PubMed
    Score: 0.928
  2. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011 Jul 20; 103(14):1093-100.
    View in: PubMed
    Score: 0.382
  3. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007 Oct 03; 99(19):1455-61.
    View in: PubMed
    Score: 0.294
  4. Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling. Clin Transl Sci. 2016 Feb; 9(1):43-50.
    View in: PubMed
    Score: 0.131
  5. Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2015 Nov 15; 21(22):5057-63.
    View in: PubMed
    Score: 0.129
  6. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2014 Aug 15; 20(16):4210-7.
    View in: PubMed
    Score: 0.119
  7. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004 Nov 15; 22(22):4442-5.
    View in: PubMed
    Score: 0.060
  8. Finding the right dose. Clin Adv Hematol Oncol. 2003 Sep; 1(9):517-8, 531.
    View in: PubMed
    Score: 0.055
  9. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1764-9.
    View in: PubMed
    Score: 0.022
  10. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010 Mar 15; 16(6):1745-55.
    View in: PubMed
    Score: 0.022
  11. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004 Nov; 76(5):490-502.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.